Two-Dose Daclizumab, Tacrolimus, Mycophenolate Mofetil, and Steroid-Free Regimen in De Novo Cardiac Transplant Recipients: Early Experience

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2163-2166

  Mastrobuoni, S ^a   Ubilla, M ^a   Cordero, A ^a   Herreros, J ^a   Rabago, G ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART GRAFT; HEART MUSCLE BIOPSY; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TACROLIMUS; TREATMENT OUTCOME;

EID: 34548668678     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.073     Document Type: Article

References (16)

1. Taylor D.O., Barr M.L., Radovancevic B., et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 18 (1999) 336
2. Reichart B., Meiser B., Vigano M., et al. European multicenter tacrolimus (FK506) heart pilot study: one-year results - European tacrolimus multicenter heart study group. J Heart Lung Transplant 17 (1998) 775
3. Kobashigawa J., Patel J., Furukawa H., et al. Five-year results of a randomized, single-center study of Tacrolimus vs Microemulsion Cyclosporine in heart transplant patients. J Heart Lung Transplant 25 (2006) 434
4. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 66 (1998) 507
5. Kobashigawa J., Miller L., Russel S., et al. Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimuus vs. Cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 (2006) 1377
6. Higgins R., Kirklin J.K., Brown R.N., et al. To induce or not to induce: do patients at great risk for fatal rejection benefit from cytolytic induction therapy?. J Heart Lung Transplant 24 (2005) 392
7. Beniaminovitz A., Itescu S., Lietz K., et al. Prevention of rejection in cardiac transplantation by blockade of the Interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342 (2000) 613
8. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352 (2005) 2705
9. Kobashigawa J., David K., Morris J., et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, Cyclosporine, and corticosteroids. Transplant Proc 37 (2005) 1333
10. Carlsen J., Johansen M., Boesgaard S., et al. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and Daclizumab in the prevention of acute rejection. J Heart Lung Transplant 24 (2005) 296
11. Chin C., Pittson S., Luikart H., et al. Induction therapy for paediatric and adult heart transplantation: comparison between OKT3 and Daclizumab. Transplantation 80 (2005) 477
12. Joyal D., Cantarovich M., Cecere R., et al. Early experience with two-dose Daclizumab in the prevention of acute rejection in cardiac transplantation. Clin Transplant 18 (2004) 493
13. Cuppoletti A., Pérez-Villa F., Vallejos I., et al. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation. Transplant Proc 37 (2005) 4036
14. Stratta R.J., Alloway R.R., Hodge H., et al. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant 16 (2002) 60
15. Vincenti F., Lantz M., Birnbaum J., et al. A phase-1 trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 63 (1997) 33
16. Eckhoff D.E., McGuire B., Sellers M., et al. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 69 (2000) 1867